Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (1122)	1/16/2003 2:18:43 PM
From: JMarcus	Respond to of 1494

The stock is certainly in a breakout mode. Message 18452107 I hadn't heard about the rumor. Interesting. Marc

To: John McCarthy who wrote (1122)	1/16/2003 9:53:38 PM
From: Dr. John M. de Castro	Read Replies (3) \| Respond to of 1494

The buyout rumor is interesting because it makes sense. Paul Freiman has made no secret of the fact that NTI was on the block. He simply recognized that no one was willing to pay what he believed the company was worth. With just Alzheimers, NTI is worth about what it's trading at. (Which by the way suggests that the downside risk is negligible). But, if the Diabetic Neuropathy trial is successful, as I believe it will be, NTI is worth 5 times its current valuation (Think 13% of a multibillion dollar market in pure profit - $130 million profit per billion in sales on a stock with less than 18 million shares outstanding. Do the math). If FRX has some preliminary evidence that the DN PIII is going to be positive, they would steal NTI at $14 per share. I hope that this rumor is false. I believe the potential is about to be realized and it's mind boggling. I've patiently waited for this day and I can wait another year for the true value to be recognized. Best regards John de C